octyl D-mannopyranoside | 189457-15-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: octyl D-mannopyranoside
• 英文别名: n-octylmannoside；(2R,3S,4S,5S)-2-(hydroxymethyl)-6-octoxyoxane-3,4,5-triol
• CAS: 189457-15-6
• 化学式: C₁₄H₂₈O₆
• 分子量: 292.373
• InChiKey: HEGSGKPQLMEBJL-JABUTEAWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  20
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  99.4
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  甘露糖 、 辛醇 在 对甲苯磺酸 作用下， 100.0 ℃ 、30.0 kPa 条件下， 生成 octyl D-mannopyranoside
  参考文献：
  名称：

  [EN] NATURALLY BASED PRESERVATIVES FOR PERSONAL CARE APPLICATIONS
  [FR] CONSERVATEURS D'ORIGINE NATURELLE POUR DES APPLICATIONS DE SOIN PERSONNEL

  摘要：

  描述了自然基础的防腐剂。更具体地说，本公开涉及一种包含烷基甘露苷的组合物，并将其用作个人护理产品中的防腐剂。烷基甘露苷，例如正辛基甘露苷，可用于减少或预防个人护理产品中微生物的生长。烷基甘露苷可与另一种自然或合成防腐剂结合使用。

  公开号：

  WO2021222262A1

文献信息

• Oligonucleotide compounds, their production and use
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0653438A2

  公开（公告）日：1995-05-17

  An oligonucleotide compound or a salt thereof, which has a nucleotide sequence represented by formula (I): wherein W represents hydrogen or a protective group; B1, B2 and B3 each represent nucleic acid residues, wherein each B2 may be the same or different when n is 2 or more; X1, X2 and X3 each represent OH, SH, C1-5 alkyl, C1 -5 alkoxy, C1 -5 monoalkylamino or an aromatic ring group which may be substituted or unsubstituted, wherein each X3 may be the same or different when n is 2 or more; R1, R2 and R3 each represent hydrogen, OH, halogen, C1 -5 alkoxy or C1 -5 alkoxyalkyloxy, wherein each R2 may be the same or different when n is 2 or more; and n represents an integer from 1 to 98 is disclosed. The oligonucleotides (I) of the present invention or the salts thereof can (1) inhibit expression of genes associated with the development of malignant tumors in malignant tumor cells, (2) inhibit expression of viral genes derived from viruses, (3) inhibit expression of genes producing proteins which contribute to the development of inflammations, (4) control expression of drug-resistant genes which cause complications in chemotherapy of malignant tumors, and (5) inhibit production of cell growth factors related to reangiostenosis after PCTA (percutaneous transluminal coronary angioplasty) by complementation to DNAs or mRNAs of genes inducing various diseases. They can be therefore used as antitumor agents, antiviral agents, antiinflammatory agents and drugs for controlling expression of specific genes such as resistance genes. These oligonucleotides can also be used as probes. Further, these oligonucleotides can be used in novel drug screening assays.

  一种寡核苷酸化合物或其盐，其核苷酸序列由式 (I) 表示： 其中 W 代表氢或保护基团；B1、B2 和 B3 各自代表核酸残基，其中当 n 为 2 或更多时，每个 B2 可相同或不同；X1、X2 和 X3 各自代表 OH、SH、C1-5 烷基、C1-5 烷氧基、C1-5 单烷基氨基或可被取代或未被取代的芳环基团，其中当 n 为 2 或更多时，每个 X3 可相同或不同；R1、R2 和 R3 各自代表氢、OH、卤素、C1 -5 烷氧基或 C1 -5 烷氧基，其中当 n 为 2 或更多时，每个 R2 可以相同或不同；n 代表 1 至 98 的整数。 本发明的寡核苷酸（I）或其盐类可以：(1) 抑制恶性肿瘤细胞中与恶性肿瘤发展有关的基因的表达；(2) 抑制来自病毒的病毒基因的表达；(3) 抑制产生有助于炎症发展的蛋白质的基因的表达、(4) 控制导致恶性肿瘤化疗并发症的耐药基因的表达，以及 (5) 通过与诱发各种疾病的基因的 DNA 或 mRNA 互补，抑制与经皮冠状动脉成形术（PCTA）后再狭窄有关的细胞生长因子的产生。因此，这些寡核苷酸可用作抗肿瘤药、抗病毒药、消炎药和控制特定基因（如抗性基因）表达的药物。这些寡核苷酸还可用作探针。此外，这些寡核苷酸还可用于新型药物筛选试验。
• Solid self-emulsifying dosage form for improved delivery of poorly soluble hydrophobic compounds and the process for preparation thereof
  申请人：AlphaRx Inc.

  公开号：US20030072798A1

  公开（公告）日：2003-04-17

  A delivery method and product for enhancing the bioavailability of an active ingredient by prolonged relatively constant release. The method involves mixing with subsequent granulation and compression of a mixture to result in a solid core tablet. The composition includes a biologically active material matrixed or otherwise contained within a hydrophobic phase with the latter absorbed onto a sorbent. The sorbent and hydrophobic phase are in a ratio of between 1:10 and 10:1. The mixture further includes a pharmaceutically acceptable surfactant. The composition, once tableted into a solid core provides spontaneous release of the biologically active material over a predetermined time frame for substantially constant bioavailability.

  一种通过延长相对稳定的释放时间来提高活性成分生物利用率的给药方法和产品。该方法包括将混合物混合，然后进行制粒和压缩，最后形成固体芯片。组合物包括一种生物活性材料，该材料以基质或其他方式包含在疏水相中，后者被吸附在吸附剂上。吸附剂和疏水相的比例在 1:10 和 10:1 之间。混合物还包括一种药学上可接受的表面活性剂。这种组合物一旦制成固体核心，就能在预定的时间内自发释放生物活性物质，使生物利用率基本保持稳定。
• ANTI-ADHESIVE COMPOUNDS TO PREVENT AND TREAT BACTERIAL INFECTIONS
  申请人：VIB vzw

  公开号：EP1755619A2

  公开（公告）日：2007-02-28
• JPH01143889A
  申请人：——

  公开号：JPH01143889A

  公开（公告）日：1989-06-06
• Anti-Adhesive Compounds to Prevent and Treat Bacterial Infections
  申请人：Berglund Jenny

  公开号：US20080171706A1

  公开（公告）日：2008-07-17

  The present invention provides compounds and compositions capable of inhibiting the attachment of Gram-negative bacteria on a host epithelium. Accordingly, said compounds and compositions can for example be used for the manufacture of a medicament to treat urinary, lung and gastrointestinal infections caused by said Gram-negative bacteria